Krsnaa Diagnostics delivers strong performance with revenues of Rs. 241 Cr, EBITDA* of Rs. 74 Cr with margins of 30.9% in H1 FY22 Revenue up by 19%, EBITDA* up by 76% and PAT without CCPS is up by 167% y-o-y

October 12, 2021

5:36 am

Krsnaa Diagnostics Ltd. (BSE: 543328 | NSE: KRSNAA) is one of India’s fastest growing diagnostic service providers, both in radiology and pathology. The Company today announced the results for first six months ending 30th September 2021, following its listing on the stock exchanges on 16th

POST TAGS:

Chair Radiology and Interventional Oncology at RGCIRC.employees Executive Director healthcare diagnostic Himachal Pradesh Karnataka Krsnaa Diagnostics Maharashtra Mr. Yash Mutha Punjab

Krsnaa Diagnostics delivers strong performance with revenues of Rs. 241 Cr, EBITDA* of Rs. 74 Cr with margins of 30.9% in H1 FY22 Revenue up by 19%, EBITDA* up by 76% and PAT without CCPS is up by 167% y-o-y

POST TAGS:

FIND US

ADDRESS

FOLLOW US ON SOCIAL MEDIA

Krsnaa Diagnostics delivers strong performance with revenues of Rs. 241 Cr, EBITDA* of Rs. 74 Cr with margins of 30.9% in H1 FY22 Revenue up by 19%, EBITDA* up by 76% and PAT without CCPS is up by 167% y-o-y

POST TAGS:

FIND US

ADDRESS

FOLLOW US ON SOCIAL MEDIA

Every major healthcare update,delivered to your inbox

Every major healthcare update,
delivered to your inbox